WCLC, YOKOHAMA, 15 - 18 OCTOBER 2017 - 1280.18

A Phase Ib trial of xentuzumab and abemaciclib in advanced or metastatic solid tumors, including advanced NSCLC

Douglas Yee, Aleix Prat, Marie Paule Sablin, Hiroji Iwata, Erica L. Johnston, Thomas Bogenrieder, Josep Serra, Hairui Hua, Patricia Lo Russo

Yee 1280.18 TiP Poster WCLC 2017

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

Insulin and IGF Signaling Receptors (IGF-1R) and Pathway Activation

Sequist LV, et al. Sci Transl Med 2011;3(75):75ra26

Phase Ib trial of afatinib and xentuzumab(BI 836845) in advanced NSCLC: dose-escalation and safety results

Park K et al. WCLC 2016 #P3.02b-005

CDK4/6 and IGF1 Receptor Inhibitors Synergize to Suppress the Growth of p16INK4A-Deficient Pancreatic Cancers

Heilmann AM, et al. Cancer Res 2014;74(14):3947–58.

Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies

Simpson A, et al. Targeted Oncol 2017 [Epub ahead of print]